Large genetic study finds no new asthma culprits in rare DNA variants
Researchers analyzing nearly 750,000 people's genetic data identified no novel genes linked to asthma through rare mutations, despite a rigorous search of the UK Biobank. The null finding suggests future asthma genetics research must refine how the disease is classified and include more diverse populations to unlock new drug targets and prevention strategies.
Originaltitel: Rare-variant collapsing analyses of asthma in the UK biobank
Asthma is a common health problem. Both common and rare genetic risk factors may contribute to asthma, but few large-scale whole-exome sequencing studies elucidating the contribution of rare variations to asthma have been published. Two published UK Biobank portals: the Genebass portal (N = 269,171) and the Astra Zeneca portal (N = 484,111) (https://azphewas.com/and https://app.genebass.org/) were used to access gene collapsing analysis of rare variations for asthma. A conservative threshold (p ≤ 2 × 10−9) was used to decrease the risk of spurious associations. Rare variations in two genes were significantly linked to asthma (Il33, FLG). Both genes have previously been linked to asthma in genome-wide association studies. The strongest non-significant gene was CSF2RA with a p-value of 6.09e-8. In conclusion, no novel significant asthma loci were identified using gene collapsing analyses. Future rare variant analysis studies of asthma need to refine phenotypic classification and incorporating diverse populations.